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Rituximab (RTX) is a monoclonal antibody; recently it has
been use as a new treatment strategy in patients with
high-degree steroid-dependent nephrotic syndrome. It
provokes a lymphocyte B depletion in some cases that
interacts with Immunoglobulins creating decreased plasma
IgG levels and hypogammaglobulinemia.
We report the case of a 2.5 year old male diagnosed
of idiopathic nephrotic syndrome. He presented resistance
to systemic steroids as well as second line treatments
(cyclophosphamide and mycophenolate). Patient started
with intravenous infussion of rituximab at 375mg/m2.
Baseline analysis before RTX treatment evidenced low IgG
levels, although these values are not conclusive because
they were taken during nephrotic state. Twenty days later,
the patient presented severe hypogammaglobulinemia
with IgG levels of 149 mg/dL, without nephrotic
proteinuria. We decided to start intravenous gamma-
globulin (IVIG) every 4-6 weeks. Analysis showed low
levels of lymphocytes (predominantly B type) four days
after initiated the treatment. Follow up demonstrated
complete recovery of lymphocyte count two years
later. After 3 years of RTX administration the patient
continues to have hypogammaglobulimenia, requiring
IVIG until now.
Comments
The cause of immunodeficiency in this patient has not yet
been established. Is it because of the nephrotic syndrome
itself? An adverse effect of the drug? Maybe a pre-existing
primary immunodeficiency?
Use of RTX has reported cases of hypogammaglobuline-
mia values usually normalizing after 11 months; persistent
hypogammaglobulinemia is not a common side effect.
We only found one series describing the association of
persistent hypogammaglobulinemia in nephrotic patients
treated with RTX, suggesting a certain predisposition
in patients with low baseline IgG levels previous to the
treatment with this monoclonal antibody.
Starting a full immune panel previous to treatment with
RTX could be a good way to predict possible persistent
hypogammaglobulinemia and to rule out immunologic
pathology before making any therapeutic decision.
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